Compare Abeona Therapeutics Inc (ABEO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Consumer Staples Select Sector SPDR Fund trades at $84.8. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | XLP | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $90.00 |
52-Week Low | $4.17 | $75.61 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XLP trades at $84.1, down 1.05% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The ETF holds a 100% buy rating from analysts and offers a 2.6% dividend yield, positioning it as a defensive play in consumer staples. Recent news highlights its role in portfolio diversification amid market volatility, with retail sales strength supporting the sector.
Outlook remains positive given analyst consensus and defensive characteristics, though risks include sector concentration and economic sensitivity. The ETF's low expense ratio and high yield appeal to income-focused investors, but competition from similar funds and macroeconomic pressures warrant monitoring for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
